A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Adaptive Biotechnologies Corporation ADPT

Promising (early) broader-coverage candidate · Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a

On FrontierLab's discovery record since 2026-07-16 (11 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-10-03), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	50.1%
Gross margin	75.4%
Gross profits / assets	0.36
Rule of 40	37.9
Net margin	-12.2%
Cash runway (months)	120
PEG	—
Price / sales	14.7

Quality checklist

✓ Revenue growth — 50.1% (pass ≥ 20%)
✓ Capital efficiency
✓ Gross margin — 75.4% (pass ≥ 60%)
✓ Gross-margin trend — 9.4 (pass ≥ 2)
✓ Share dilution — 3.7%

Fundamentals — snapshot as of 2026-10-03

Stage	Early
Share issuance (YoY)	3.7% · modest issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-0.41
Burn multiple	0.1
Gross-margin trend (pts)	9.4
Cash / assets	0.54
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-04

Momentum context — a snapshot from 2026-10-03, not current

Price at surface	$28.35 (as of 2026-10-03)
52-week range	$12 – $29.96
% off 52-wk high	-5.4%
RSI (14)	59
Relative volume	0.6×

Risk flags

Burning cash — operating margin is negative.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-10-03 (end-of-day). How grades are computed →